This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
by Zacks Equity Research
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
RDYNegative Net Change RHHBYNegative Net Change AMGNNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
by Ekta Bagri
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
BMYNegative Net Change JNJPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
by Zacks Equity Research
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Genentech Expands Investment in North Carolina Facility to $2B
by Zacks Equity Research
Roche more than doubles Genentech's Holly Springs biomanufacturing investment to approximately $2B, boosting U.S. supply-chain resilience and metabolic drug production.
NVSNegative Net Change RHHBYNegative Net Change JNJPositive Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
by Zacks Equity Research
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
ALKSPositive Net Change FOLDNegative Net Change KRYSNegative Net Change IBRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
by Zacks Equity Research
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
GSKNegative Net Change JNJPositive Net Change MRKNegative Net Change RAPTPositive Net Change
biotechs
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
by Zacks Equity Research
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
NVONegative Net Change ALKSPositive Net Change FOLDNegative Net Change KRYSNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer
by Zacks Equity Research
NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.
SNYNegative Net Change MNKDPositive Net Change PFENegative Net Change NVAXNegative Net Change
biotechs
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
MNKDPositive Net Change FOLDNegative Net Change MRKRNegative Net Change KROSNegative Net Change
biotechs
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious
GSKNegative Net Change BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals